Vertex Pharmaceuticals
VRTX
$519.51
+0.79%
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs, with its franchise anchored in cystic fibrosis therapies including Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi, and Symdeko, alongside expanding positions in gene editing via Casgevy and non-opioid pain management via Journavx. Vertex is the dominant, near-monopolistic standard of care in CF globally, a rare position of pricing power and durability in biotech, and it is now attempting to parlay that cash generation into a diversified, multi-franchise platform spanning sickle-cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes cell therapy, and endocrine/pain assets. The current investor narrative centers on the $10 billion acquisition of Crinetics Pharmaceuticals — struck at a reported 102% premium — which management and sell-side bulls argue could add roughly $5 billion in annual revenue and extend the growth runway beyond CF, while skeptics question the price paid and the binary clinical risk of the acquired pipeline. Sentiment has been further shaped by a rival's CF setback that reinforced Vertex's moat, strong pediatric Casgevy efficacy data, and a stock that has rallied roughly 14% since its last earnings report even as mixed quarterly results and soft near-term momentum scores keep some analysts cautious.…
VRTX
Vertex Pharmaceuticals
$519.51
Related headlines
Investment Opinion: Should I buy VRTX Today?
We assign a Hold rating on VRTX. The core thesis is that Vertex is a high-quality, cash-generative biotech with a dominant CF franchise and a promising but unproven diversification pipeline, yet the current valuation already reflects much of the optimism. The analyst consensus is Buy with a mean rating of 1.67 and an average target of $569.19, implying 10.4% upside, which is modest relative to the risks.
The supporting evidence includes: 1) Revenue growth of 7.82% YoY in Q1 2026, which is solid but decelerating; 2) Exceptional profitability with a 34.53% net margin and 86.85% gross margin; 3) Fortress balance sheet with debt-to-equity of 0.208 and $5.505 billion in cash; 4) Strong free cash flow of $3.710 billion TTM, funding buybacks and M&A; and 5) A premium valuation with trailing P/E of 29.3x and PS of 9.6x, above the large-cap biotech range of 15x-25x earnings and 5x-8x sales. The implied upside to the average target is only 10.4%, while the downside to the low target is 32.1%, suggesting an unfavorable risk/reward at current levels.
The biggest risks that could invalidate the thesis are: 1) A clinical failure or delay in the Crinetics pipeline, which could lead to a multi-billion write-down and derail the diversification story; 2) Further deceleration in CF revenue growth below 5% YoY, which would pressure the multiple; and 3) Regulatory or reimbursement headwinds for Casgevy or Journavx. We would upgrade to Buy if the stock pulls back to the $450-$470 range (implying a forward P/E below 22x) or if Crinetics shows clear commercial traction. We would downgrade to Sell if CF revenue declines or if the Crinetics integration fails to deliver. Relative to its history and peers, VRTX appears fairly valued to modestly overvalued, with the market pricing in successful execution of its diversification strategy.
Sign up to view all
VRTX 12-Month Price Forecast
Vertex is a high-quality biotech with a dominant CF franchise and a strong balance sheet, but the stock appears fairly valued to modestly overvalued after a 29.7% one-year rally. The deceleration in revenue growth and the premium multiple suggest limited upside unless the Crinetics acquisition and pipeline assets deliver substantial revenue ahead of expectations. The low beta (0.32) and defensive characteristics make it a core holding, but the risk/reward is balanced. We would upgrade to bullish if the stock pulls back to the $450-$470 range or if Crinetics shows clear commercial traction; we would downgrade to bearish if CF revenue declines or if the Crinetics integration fails to deliver.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Vertex Pharmaceuticals's 12-month outlook, with a consensus price target around $569.19 and implied upside of +9.6% versus the current price.
Average Target
$569.19
0 analysts
Implied Upside
+9.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$350 - $672
Analyst target range
Vertex is covered by 27 analysts, and the consensus recommendation is a Buy with a recommendation mean of 1.67 (where 1.0 is a Strong Buy and 3.0 is a Hold), reflecting a broadly bullish but not unanimous stance. The average target price is $569.19, which implies roughly 10.4% upside from the current price of $515.44, and the consensus EPS estimate of $34.10 and revenue estimate of $20.19 billion for the forward period underpin that target. The sentiment leans constructive — the institutional ratings show a preponderance of Buy/Outperform/Overweight calls from Truist, UBS, RBC, Barclays, Morgan Stanley, and Bernstein — but the presence of a persistent Underperform rating from Baird and Hold ratings from Canaccord Genuity indicates the bull case is not without credible dissent, and the modest 10.4% implied upside suggests the market has already largely priced in the consensus view. The target range is wide, spanning $350.00 on the low end to $672.00 on the high end — a 92% spread between the two — which signals meaningful disagreement about the company's trajectory and, by extension, high uncertainty. The high target of $672.00 implies roughly 30% upside and likely assumes successful Crinetics integration delivering the promised $5 billion in annual revenue, continued Casgevy adoption, Journavx traction, and multiple expansion back toward the upper end of Vertex's historical band; the low target of $350.00 implies roughly 32% downside and prices in CF growth stalling, pipeline disappointments, margin compression from the Crinetics premium, and multiple contraction toward the low end of the historical range. The recent institutional ratings flow is essentially static — the July 2026 actions from Truist, UBS, Baird, and RBC were all reiterations rather than upgrades or downgrades — which suggests analysts are in a holding pattern awaiting clearer evidence on the Crinetics deal and the diversification pipeline before adjusting estimates. Given the wide spread and the low-beta, high-quality nature of the stock, the analyst community appears to view Vertex as a core holding with limited near-term catalysts rather than a high-conviction tactical idea.
Drowning in data?
Find the real signal!
Bulls vs Bears: VRTX Investment Factors
The bull case rests on Vertex's entrenched CF monopoly, fortress balance sheet, and a promising diversification pipeline that could add $5 billion in annual revenue. The bear case centers on decelerating revenue growth (7.82% YoY), a premium valuation (29.3x trailing P/E, 9.6x PS), and the binary risk of the $10 billion Crinetics acquisition. Currently, the bear evidence appears slightly stronger because the core CF franchise is maturing and the valuation already prices in successful diversification, leaving limited margin for error. The most critical tension is whether the Crinetics deal and other pipeline assets can scale fast enough to offset CF deceleration and justify the premium multiple. If Crinetics delivers, the stock could re-rate higher; if it disappoints, multiple compression could drive significant downside.
Bullish
- CF franchise dominance reinforced by rival setback: Vertex's cystic fibrosis portfolio generated $2.779 billion in Q1 2026 (Trikafta/Kaftrio $2.355B + Alyftrek $424.4M), representing 93% of total revenue. A rival's recent CF failure further entrenches Vertex's near-monopoly, providing durable pricing power and a wide moat that supports 86.85% gross margins.
- Fortress balance sheet with ample M&A capacity: Debt-to-equity is just 0.208, current ratio is 2.90, and cash stood at $5.505 billion at Q1 2026. TTM free cash flow of $3.710 billion and Q1 FCF of $1.295 billion demonstrate the company can self-fund R&D and the $10 billion Crinetics acquisition without external financing.
- Exceptional profitability and cash generation: Q1 2026 net margin was 34.53%, operating margin 38.10%, and ROE 21.18%. Net income grew 59.6% year-over-year from $646 million in Q1 2025 to $1.031 billion in Q1 2026, showcasing strong operating leverage.
- Diversification pipeline offers multi-billion revenue potential: The $10 billion Crinetics acquisition could add roughly $5 billion in annual revenue, while Casgevy's 100% efficacy in pediatric trials and Journavx's non-opioid pain approval open new multi-billion markets. These assets are still small ($135.9M in other products) but provide a long growth runway beyond CF.
Bearish
- Revenue growth decelerating sharply: Q1 2026 revenue grew only 7.82% YoY to $2.987 billion, down from double-digit historical rates, and declined 7.4% sequentially from Q4 2025's $3.227 billion. This deceleration pressures the premium multiple and raises questions about the sustainability of mid-teens earnings growth implied by the forward P/E.
- Premium valuation leaves little room for error: Trailing P/E of 29.32x and forward P/E of 25.60x are above the large-cap biotech range of 15x-25x, while PS of 9.60x and EV/Sales of 9.90x are rich for high-single-digit revenue growth. The stock trades at a premium to peers and its own historical median P/E in the mid-20s.
- Crinetics acquisition carries binary clinical risk: The $10 billion price tag represents a 102% premium, and the acquired pipeline's success is uncertain. If the lead asset fails or underperforms, Vertex could face a multi-billion write-down and a significant hit to earnings, undermining the diversification thesis.
- Recent momentum has turned negative: The stock is down 1.96% over the past month versus a 1.06% decline for SPY, with a negative 1-month relative strength of -0.90. The 6-month relative strength is also negative at -5.58%, suggesting the stock may be losing leadership after a strong run.
VRTX Technical Analysis
Vertex is in a sustained, multi-quarter uptrend, with the shares up 29.71% over the trailing twelve months and 14.00% year-to-date, and the current price of $515.44 sits at roughly 79% of the 52-week range bounded by a $374.17 low and a $560.25 high. That positioning — well above the midpoint but still about 8% below the absolute high — indicates a stock with durable momentum that has recently cooled from its peak rather than one that is either overextended at the highs or broken down toward the lows. The 15.85% three-month gain confirms the intermediate trend remains constructive, and the fact that the 1-year return of 29.71% has outpaced the S&P 500's 16.22% by a relative-strength spread of 13.49 percentage points underscores genuine leadership rather than beta-driven drift. Recent momentum, however, has decelerated sharply: the stock is down 1.96% over the past month versus a 1.06% decline for SPY, producing a negative 1-month relative strength of -0.90, and the last four sessions alone have slid from $546.12 to $515.44. This creates a clear divergence — the 1-year and 3-month trends are strongly positive while the 1-month trend is negative — which most plausibly signals a healthy pullback within an uptrend following the August run to $557.96, though it could also mark the early stages of mean reversion after a sharp 6-month relative-strength lag of -5.58 percentage points versus the index. With a beta of just 0.32, Vertex is roughly 68% less volatile than the broad market, meaning this drawdown is modest in absolute terms and the stock's low-beta defensive profile argues for smaller position-sizing adjustments than the headline price swings might suggest. Key technical levels are well defined: resistance sits at the 52-week high of $560.25, and a decisive breakout above that level would confirm the resumption of the primary uptrend and likely invite momentum buyers, while support rests at the 52-week low of $374.17, with intermediate support likely in the $490–$500 zone where the stock consolidated in July. A breakdown below $490 would threaten the 3-month uptrend structure and put the $466–$470 June lows in play, whereas the maximum drawdown of -15.21% over the period suggests downside has historically been contained; given the 0.32 beta and a short ratio of 3.92, the setup favors buying weakness rather than chasing strength.
Beta
0.32
0.32x market volatility
Max Drawdown
-15.2%
Largest decline past year
52-Week Range
$374-$560
Price range past year
Annual Return
+31.7%
Cumulative gain past year
| Period | VRTX Return | S&P 500 |
|---|---|---|
| 1m | +2.7% | -2.0% |
| 3m | +14.6% | +1.4% |
| 6m | +15.0% | +15.0% |
| 1y | +31.7% | +15.7% |
| ytd | +14.9% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VRTX Fundamental Analysis
Vertex's revenue trajectory remains solidly growing but is decelerating at the margin: Q1 2026 revenue of $2.987 billion rose 7.82% year-over-year, a marked slowdown from the sequential cadence of $2.770 billion in Q1 2025, $2.965 billion in Q2 2025, $3.076 billion in Q3 2025, and $3.227 billion in Q4 2025, with the Q1 2026 figure actually declining 7.4% sequentially from the Q4 peak. The revenue mix is overwhelmingly concentrated in the CF franchise, with Trikafta/Kaftrio contributing $2.355 billion and the newer Alyftrek adding $424.4 million, while all other manufactured products contribute just $135.9 million — meaning the diversification story (Casgevy, Journavx, and the pending Crinetics assets) is still a small fraction of the top line and the investment case hinges on whether those new engines can scale before CF growth matures. The 7.82% YoY growth rate is respectable for a company of this size but represents a meaningful deceleration from the double-digit growth the market has historically rewarded, which explains why the stock's multiple has compressed even as the share price has risen. Profitability is exceptional: Q1 2026 net income of $1.031 billion on $2.987 billion of revenue produced a 34.53% net margin, with a gross margin of 86.85% and an operating margin of 38.10%, and the gross margin has been remarkably stable in the 85.5%–86.9% band across the last five quarters. The one blemish is the Q2 2024 quarter, when a $5.4 billion R&D charge (likely an acquired IPR&D write-off) drove a -$3.594 billion net loss and a -135.8% net margin, but that was a one-time event; since then, net income has compounded from $646 million in Q1 2025 to $1.031 billion in Q1 2026, a 59.6% increase, and the trailing P/E of 29.3x reflects a company that is now solidly and consistently profitable. The balance sheet is fortress-like: debt-to-equity of just 0.208, a current ratio of 2.90, cash of $5.505 billion at the end of Q1 2026, and interest coverage so high that interest expense is effectively immaterial. Free cash flow is robust at $1.295 billion in Q1 2026 (against $1.428 billion of operating cash flow and $133.4 million of capex), with TTM free cash flow of $3.710 billion, and the company returned capital via $336.9 million of buybacks in the quarter while still growing its cash balance by $417.1 million — evidence that Vertex funds its R&D and M&A internally without external financing. ROE of 21.18% and ROA of 11.93% confirm high-quality capital deployment, and the 0.209 debt-to-equity ratio leaves ample capacity for further bolt-on acquisitions like Crinetics without straining the balance sheet.
Quarterly Revenue
$3.0B
2026-03
Revenue YoY Growth
+7.8%
YoY Comparison
Gross Margin
86.9%
Latest Quarter
Free Cash Flow
$3.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VRTX Overvalued?
Because Vertex is solidly profitable — Q1 2026 net income of $1.031 billion and a trailing P/E of 29.32x — the PE ratio is the appropriate primary valuation metric, and the gap between the trailing 29.32x and the forward 25.60x implies the market expects roughly 14.5% earnings growth over the next twelve months, consistent with consensus EPS of $34.10 versus the current run-rate. That forward compression is meaningful but not dramatic, suggesting the market is pricing in steady mid-teens earnings growth rather than an acceleration, which is a reasonable but not aggressive assumption given the 7.82% revenue growth and the pending Crinetics integration. On the other hand, the PEG ratio of -0.035 is distorted by the trailing EPS base and should be disregarded; the more informative cross-check is the PS ratio of 9.60x and EV/Sales of 9.90x, which are rich for a company growing revenue at high-single digits. Relative to the biotechnology sector, where large-cap profitable biotechs typically trade in the 15x–25x forward earnings range and 5x–8x sales, Vertex's 25.60x forward P/E and 9.60x PS represent a premium — roughly a 10%–25% premium on earnings and a 20%–90% premium on sales depending on the peer set. That premium is defensible on the basis of Vertex's 86.85% gross margin, 34.53% net margin, 21.18% ROE, and near-monopoly CF franchise, but it leaves little room for execution error, particularly if CF growth continues to decelerate or the Crinetics deal fails to deliver the promised $5 billion revenue opportunity. Historically, Vertex's own valuation band has been wide: the trailing P/E has ranged from roughly 13.7x (Q3 2021) to 48.1x (Q1 2025), and the PS ratio from about 23.6x (Q3 2021) to 46.0x (Q2 2024), with the current 29.32x P/E sitting in the lower-middle portion of that historical range and the 9.60x PS sitting at the very bottom. The PS compression is largely a function of revenue scaling faster than the multiple, but the P/E at 29.3x versus a 5-year median in the mid-20s suggests the stock is not cheap on its own history — it is fairly valued to modestly expensive, with the market already pricing in successful diversification and the Crinetics accretion. In short, the valuation embeds optimistic expectations: investors are paying a premium to peers and a mid-to-high multiple versus history for a company whose core franchise is maturing, making the risk/reward balanced rather than compelling at current levels.
PE
29.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 14x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.6x
Enterprise Value Multiple
Investment Risk Disclosure
Vertex's financial risks are relatively contained but not negligible. The company carries minimal debt (debt-to-equity 0.208) and has a strong cash position of $5.505 billion, but the $10 billion Crinetics acquisition introduces integration risk and potential write-downs if the pipeline fails. Revenue is highly concentrated in CF, with Trikafta/Kaftrio and Alyftrek accounting for 93% of Q1 2026 revenue, making the company vulnerable to competitive threats or pricing pressure in that franchise. Additionally, the 7.82% YoY revenue growth in Q1 2026 is a sharp deceleration from prior periods, and any further slowdown could pressure margins and earnings growth.
Market and competitive risks are significant given Vertex's premium valuation. The stock trades at 29.3x trailing earnings and 9.6x sales, well above large-cap biotech peers, leaving it exposed to multiple compression if growth disappoints. The beta of 0.32 indicates low correlation with the broader market, which is a defensive attribute, but sector rotation away from high-multiple healthcare names could still weigh on the shares. Competitive risks include potential new CF therapies from rivals, though a recent rival setback has reinforced Vertex's moat. Regulatory and reimbursement pressures in the U.S. and Europe could also impact pricing and adoption of new therapies like Casgevy and Journavx.
The worst-case scenario would involve a combination of CF revenue stagnation, a major clinical failure in the Crinetics pipeline, and multiple contraction. In such a scenario, the stock could fall to its 52-week low of $374.17, representing a 27.4% decline from the current price of $515.44. The analyst low target of $350 implies a 32.1% downside. A more severe outcome, such as a complete write-off of the Crinetics acquisition and loss of CF exclusivity, could push the stock below $350, but that is less likely given the strength of the CF franchise and the company's cash generation.
FAQ
The key risks include: 1) Revenue concentration in CF (93% of Q1 2026 revenue), making the company vulnerable to competitive or pricing pressures; 2) Decelerating growth, with Q1 2026 revenue up only 7.82% YoY and down 7.4% sequentially; 3) The $10 billion Crinetics acquisition at a 102% premium carries binary clinical and integration risk; 4) Premium valuation (29.3x P/E, 9.6x PS) leaves downside if growth disappoints; and 5) Regulatory and reimbursement headwinds for new therapies like Casgevy and Journavx. The most severe risk is a clinical failure in the Crinetics pipeline, which could trigger a write-down and multiple compression, potentially driving the stock to the $350-$374 range.
Our 12-month forecast has three scenarios: Bull (25% probability, $620-$672) assumes successful Crinetics integration, strong Casgevy and Journavx uptake, and multiple expansion; Base (55% probability, $540-$590) assumes steady execution with mid-single-digit CF growth and modest Crinetics contribution, aligning with the analyst average target of $569; Bear (20% probability, $350-$420) assumes CF stagnation, Crinetics failure, and multiple compression. The base case is most likely, hinging on CF revenue stability and no major pipeline setbacks. The analyst consensus target of $569 implies 10.4% upside, but the wide range ($350-$672) reflects significant uncertainty.
VRTX appears fairly valued to modestly overvalued. Its trailing P/E of 29.3x and forward P/E of 25.6x are above the large-cap biotech range of 15-25x, and its PS of 9.6x and EV/Sales of 9.9x are rich compared to peers at 5-8x sales. Relative to its own history, the P/E is in the lower-middle of its 5-year range (13.7x-48.1x), but the PS is at the very bottom due to revenue scaling. The premium is justified by Vertex's 86.85% gross margin, 34.53% net margin, and CF monopoly, but it leaves little room for error. The market is pricing in successful diversification and mid-teens earnings growth, which may be optimistic given the 7.82% revenue growth.
VRTX is a high-quality biotech with a dominant CF franchise, a fortress balance sheet, and a promising pipeline, but the current valuation offers limited upside. The stock trades at 29.3x trailing earnings and 9.6x sales, above peers, with analyst average target of $569 implying just 10.4% upside. The biggest downside risk is a clinical failure or integration misstep with the $10 billion Crinetics acquisition, which could send shares to the $350-$374 range (27-32% downside). For long-term investors comfortable with binary biotech risk and seeking a lower-beta healthcare holding, VRTX is a reasonable buy on pullbacks. However, at current levels, the risk/reward is balanced, making it more of a Hold for most investors.
VRTX is best suited for long-term investment (minimum 3-5 years) given its low beta (0.32), strong cash flow, and pipeline optionality. The company does not pay a dividend, so returns depend on capital appreciation and successful pipeline development. Short-term trading is less attractive due to the stock's low volatility and the binary nature of clinical catalysts. Earnings visibility is high for the CF franchise but lower for the diversification pipeline. Investors should be prepared for periods of stagnation as the company invests in R&D and integrates acquisitions. A long-term holding period allows time for Crinetics, Casgevy, and Journavx to contribute meaningfully, potentially driving the next leg of growth.
